THER (Theralink Technologies) YoY EBITDA Growth: 66.67% (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Theralink Technologies YoY EBITDA Growth?

Theralink Technologies THER -99.00% YoY EBITDA Growth is 66.67% as of Dec. 2023.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Theralink Technologies's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 66.67%.

Theralink Technologies's EBITDA per Share for the three months ended in Dec. 2023 was $-0.00.

Theralink Technologies YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Theralink Technologies's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralink Technologies YoY EBITDA Growth Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -226.63 99.77 97.22 -100.00 0.00

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 300.00 66.67

Theralink Technologies YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Theralink Technologies's YoY EBITDA Growth for the fiscal year that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (A: Sep. 2023 )
=(EBITDA per Share (A: Sep. 2023 )-EBITDA per Share (A: Sep. 2022 ))/ | EBITDA per Share (A: Sep. 2022 ) |
=(-0.002--0.002)/ | -0.002 |
=0.00 %

Theralink Technologies's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.002--0.006)/ | -0.006 |
=66.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 66.67% mean?
Theralink Technologies (THER) has a YoY EBITDA Growth of 66.67% as of Dec. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Theralink Technologies and its competitors.
Is Theralink Technologies' YoY EBITDA Growth too high?
Theralink Technologies' current YoY EBITDA Growth is 66.67%.
How does Theralink Technologies' YoY EBITDA Growth compare to AXIM and ISCO?
Theralink Technologies' YoY EBITDA Growth of 66.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Theralink Technologies and its competitors. Theralink Technologies's current YoY EBITDA Growth is 66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralink Technologies stock overvalued right now?
Theralink Technologies (THER) has a current YoY EBITDA Growth of 66.67%. The current YoY EBITDA Growth is 66.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Theralink Technologies (THER), the current YoY EBITDA Growth is 66.67% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theralink Technologies Business Description

Address 15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.